OEL Fastrac Catalog

Please note, this OEL/ADE monograph also applies to Sodium antipyrine (CAS RN 12379-37-2) and Antipyrine salicylate (CAS RN 520-07-0). Antipyrine, also known as phenazone, is an analgesic, antipyretic, and anti-inflammatory drug. It is a nonsteroidal anti-inflammatory drug (NSAID). The mechanism of action of antipyrine is multifaceted (7). Antipyrine is thought to act primarily in the central nervous system (CNS), increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, cyclooxygenase (COX)-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis. Prostaglandins are lipid compounds that play key roles in inflammation and pain signaling pathways. By inhibiting these enzymes, antipyrine effectively reduces the production of prostaglandins, thereby diminishing inflammation and pain. Additionally, antipyrine's antipyretic properties are believed to be mediated through its effects on the hypothalamus, the part of the brain responsible for regulating body temperature. By altering the hypothalamic set point for temperature control, the drug helps to reduce fever.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Antipyrine, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.